Helen Mogun, MS

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

JCP
Atomoxetine and Prevalence of Major Congenital Malformations
Original Research

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ January 16, 2023

Little is known about the safety of atomoxetine, a non-stimulant treatment for attention-deficit/hyperactivity disorder. This study assessed the prevalence of major congenital malformations after first-trimester exposure to atomoxetine.
Gabriella Bröms, Sonia Hernández-Díaz, Krista F. Huybrechts, et al
JCP
Original Research

June 18, 2019

Women who take mood stabilizers have a greater risk of placenta-mediated pregnancy complications. But are the mood stabilizers themselves responsible for this higher risk? This study explores that question.
Jacqueline M. Cohen, Krista F. Huybrechts, Elisabetta Patorno, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe